Placement of Entitlement Offer Shortfall
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Neurizon Therapeutics Limited has announced a placement of entitlement offer shortfall to raise funds, supported by new and existing investors. The announcement confirms that the company remains funded for participation in a significant clinical trial.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- NUZ-001 Data Shows Multi-Pathway Protein Clearance
- Neurizon announces leadership transition
- Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial
- Neurizon Initiates Dosing in HEALEY ALS Platform Trial
- Appendix 4D - Half-year Financial Report - 31 December 2025
Later from Neurizon Therapeutics
- Ethics Approval Received for NUZ-001 Oral Liquid P1 Study
- HEALEY ALS Trial Regimen I Expands to 240 Participants
- HEALEY ALS Platform Trial Regimen I expands to 240 participants
- HEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule
- Neurizon executes long-term supply agreement with Elanco
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics